Learn More

Targeted Radioisotope Therapy Webinar Series

The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.

Healthcare Provider

Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.

What are Nuclear Medicine and Molecular Imaging?

Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.

Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and  other diseases.

Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:

  • provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery
  • identify disease in its earliest stages and determine the exact location of a tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests

Learn More

 

Disease-Specific Information

Oncology

Cancer Scan

Cardiology

Heart Scan

Neurology

Brain Scan

Guidance

SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.

Guidelines
Appropriate Use Criteria
Dosimetry
Dose Optimization

Related Resources

NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary

Ordering Information

The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:

  • Sample Request Forms
  • Sample Letters of Medical Necessity
  • Sample Reports from Nuclear Medicine Physician
  • CMS Decision Memos

Learn More

Request a Speaker

SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.

Outreach Speaker Request Form
Outreach Program
FAQs

 

 

  • July 18, 2014AAIC: F-18 Flute shown to change management in 20% of dementia patients

    The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed how patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer's disease. Another study of early onset dementia patients showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET.
    (MI: Making a Difference)

  • July 17, 2014PET agents differentiate Alzheimer's, cardiovascular disease

    Researchers have found that using PET brain imaging with florbetapir and FDG can differentiate cardiovascular disease from symptoms of mild cognitive impairment or Alzheimer's disease. The combination can also detect amyloid plaques in patients with cardiovascular disease.
    (MI: Making a Difference)

  • July 16, 2014PET imaging for myocardial innervation expands with F-18 labeled agent

    First-in-human study of an investigational radiotracer, F-18 LMI1195, shows clear imaging of myocardial innervation via the norepinephrine transporter system—tipping off potential adverse cardiac events, according to a study published July 3 in the Journal of Nuclear Medicine .
    (MI: Making a Difference)

  • July 14, 2014Amino-acid PET imaging of gliomas in the spotlight

    Amino-acid biomarkers have undergone an evolution in the imaging of gliomas. Several agents have shown to be particularly useful, most notably C-11 MET, F-18 FDOPA, FLT and FET, according to a review of amino-acid imaging published July 8 in the Journal of Nuclear Medicine .
    (MI: Making a Difference)

Featured Resources

  • Guidance

    Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.

  • SNMMI Journals

    Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.

  • Legislative Issues

    SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.

  • Annual Reports